Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Intermenstrual bleeding, Menstrual disorder, Vaginal haemorrhage
Clinical narrative: Since her second covid vaccine, she has spotting starting the day after ovulation until her period begins. This has happened every month since her second vaccine.; Patient has spotting (abnormal vaginal bleeding) starting the day after ovulation until her period begins; Since her second covid vaccine, she has spotting starting the day after ovulation until her period begins. This has happened every month since her second vaccine.; This is a spontaneous report from a contactable consumer (reported for herself). A 30-years old female non-pregnant patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot Number: EN6205/Batch number was not reported), dose 2 via an unspecified route of administration on 05Mar2021 (at the age of 29-years-old) as dose 2, single for covid-19 immunisation at student health clinic. The patient medical history was not reported. Concomitant medication(s) included progesterone (PROGESTERONE) taken for an unspecified indication, start and stop date were not reported; ascorbic acid, betacarotene, calcium sulfate, colecalciferol, cyanocobalamin, ferrous fumarate, folic acid, nicotinamide, pyridoxine hydrochloride, retinol acetate, riboflavin, thiamine mononitrate, tocopheryl acetate, zinc oxide (PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE]) taken for an unspecified indication, start and stop date were not reported; colecalciferol (D3 VITAMIN) taken for an unspecified indication, start and stop date were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient has no reported allergies. The patient previously received first dose bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot Number: EL9267/Batch number was not reported), dose 1 via an unspecified route of administration right arm on 12Feb2021 at 12:00 PM as dose 1, single for covid-19 immunisation at student health clinic. On 21Apr2021, consumer reported that Since her second covid vaccine, she has spotting (abnormal vaginal bleeding) starting the day after ovulation until her period begins. This has happened every month since her second vaccine. Before the vaccine, she could spot a week after ovulation until her period. She could start progesterone 200 mg nightly around 4 days after ovulation to avoid this spotting. There was a strong correlation between her second vaccine and now starting to bleed consistently the day after ovulation until her period. She needs to start progesterone the day of ovulation in order to not spot during the luteal phase. Her and her husband are actively trying to conceive. The reporter stated the events result in doctor or other healthcare professional office/clinic visit. It was unknown if patient receive treatment for the events. The outcome of the events was not resolved.  Follow-up attempts are completed. No further information is expected.